Prenosis

Prenosis develops data-driven diagnostic tools and precision medicine solutions for acute care conditions.

Active

Updated: Mar 15, 2026 ·

About

Prenosis is a biology-based technology company established in 2014, with its headquarters located in Chicago, Illinois. The company specializes in developing data-driven diagnostic tools and precision medicine solutions specifically for acute care environments. Its foundational belief is that healthcare should be tailored to individual biology, a principle it applies through innovative technological approaches.

Recent News & Mentions

Jan 29, 2026FundingPrenosis - Series A

Financial History

Prenosis has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in January 2026.

Total Raised

$20.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Jan 29, 2026	$20.0M Series A	PACE Healthcare Capital	Carle, Global Health Investment Corporation, Illinois Department of Commerce & Economic Opportunity, LabCorp Venture Fund, UCI Health, UC Investments

Financial History

Prenosis has raised $20.0M across 1 funding round.

Total Raised

$20.0M

Valuation

N/A

Deep Dive

The company leverages artificial intelligence to interpret complex patient data, aiming to provide predictive insights that support clinical decision-making. This technology is designed to integrate seamlessly into existing clinical workflows, enhancing the ability of healthcare providers to manage acute conditions more effectively.

Prenosis's focus on acute care addresses the need for rapid and accurate diagnostics in critical situations. By combining advanced AI with biological understanding, the company seeks to improve patient outcomes through more personalized and timely interventions.

A significant achievement for Prenosis is the FDA De Novo marketing authorization of its Immunoscore product. This AI-powered diagnostic tool is specifically designed for sepsis, a life-threatening condition requiring prompt and precise diagnosis. The authorization underscores the company's commitment to bringing validated, data-driven solutions to market.

Through its continuous research and development, Prenosis aims to advance the field of precision medicine. The company's efforts are directed towards transforming how acute care conditions are diagnosed and managed, ultimately serving patients with more individualized and effective treatments.

Sources

Frequently Asked Questions

What specific regulatory milestone has Prenosis achieved for its diagnostic technology?

Prenosis has received FDA De Novo marketing authorization for its Immunoscore product, an AI-powered diagnostic tool designed for sepsis.

How does Prenosis integrate its technology into clinical practice?

Prenosis supports the integration of its technology into clinical workflows to help interpret complex patient data and provide predictive insights for acute care.